Peptide API Documentation for Regulatory Submissions: What Procurement and QA Teams Need to Know

When sourcing peptide APIs for pharmaceutical development, procurement and QA teams must ensure that the supplier provides comprehensive documentation to support regulatory submissions. Peptide API documentation for regulatory submissions typically includes a drug master file (DMF), certificate of analysis (COA), and detailed manufacturing information. Without these, your submission may face delays or rejection. This article outlines the key documents and how to evaluate supplier readiness.

The first critical document is the drug master file (DMF). A DMF is a confidential submission to the FDA or other regulatory agencies that provides detailed information about the manufacturing facility, process, and controls. For peptides, a Type II DMF is common. Procurement teams should verify that the supplier has an active DMF and can provide a letter of authorization (LOA) for your submission. This ensures the agency can review the DMF directly.

Another essential document is the certificate of analysis (COA). The COA should include test results for identity, purity, and impurities, along with the methods used. For regulatory submissions, the COA must be generated under cGMP conditions. QA teams should review the COA to ensure it meets specifications and that the analytical methods are validated. Any deviations should be documented and explained.

The chemistry, manufacturing, and controls (CMC) section of your submission requires detailed information about the peptide's manufacturing process, characterization, and stability. Suppliers should provide a comprehensive CMC package, including process flow diagrams, raw material specifications, and in-process controls. This information is critical for demonstrating consistent quality and safety. Procurement should confirm that the supplier can support CMC queries from regulators.

Stability data is another key component. Regulatory agencies require stability studies to establish retest periods and storage conditions. Suppliers should provide stability protocols and data from both accelerated and long-term studies. QA teams should evaluate whether the data supports the proposed storage conditions and shelf life. Incomplete stability data can lead to additional questions during review.

For injectable peptides, sterility and endotoxin testing are mandatory. Suppliers must provide documentation for these tests, along with validation of the analytical methods. Procurement should verify that the supplier has appropriate facilities and controls for sterile processing. If the supplier does not have in-house capabilities, they should provide documentation from qualified contractors.